A Prospective Study Evaluating the Treatment of Knee Osteoarthritis With the Cryo-Touch III Device

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
MyoScience, Inc
ClinicalTrials.gov Identifier:
NCT01704157
First received: October 5, 2012
Last updated: January 27, 2014
Last verified: January 2014
  Purpose

A proof of concept study to evaluate the feasibility of safe and effective treatment through optimization of the Cryo-Touch III device for temporary relief of pain.


Condition Intervention
Osteoarthritis of the Knee
Device: Cryo-Touch III

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective Non-Randomized Unblinded Study Evaluating the Treatment of Knee Osteoarthritis With the Cryo-Touch III Device

Resource links provided by NLM:


Further study details as provided by MyoScience, Inc:

Primary Outcome Measures:
  • An improvement in the Visual Analog Scale (VAS) for pain at Day 7 [ Time Frame: Screening (Day -30 to Day 0), Visit 2 (Day 0), Visit 3 (Day 7), Visit 4 (Day 30) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Improvement (pain, stiffness, and functionality) as determined by WOMAC Scale at Day 7. [ Time Frame: Visit 2 (Day 0), Visit 3 (Day 7) ] [ Designated as safety issue: No ]
    A significant difference is observed as >/= 2-points

  • Duration of Treatment Effect [ Time Frame: Visit 3 (Day 7), Visit 4 (Day 30), Visit 5 (Day 56) ] [ Designated as safety issue: No ]
  • Analgesic Use [ Time Frame: Screening thru Visit 5 (Day 56) ] [ Designated as safety issue: No ]

Enrollment: 33
Study Start Date: September 2012
Study Completion Date: July 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Open Treatment
Treatment with Cryo-Touch III Device
Device: Cryo-Touch III
Study treatment at Day 0.

Detailed Description:

Over 100 million patients in the United States suffer from chronic pain. Chronic pain conditions are often debilitating, taking a toll on a patient's physical and mental welfare. Though a variety of pain management techniques currently exist, the most common nonsurgical options provide slow-acting and/or short-term relief. Medication, often in the form of non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, comes with an array of side effects such as nausea and vomiting. Medication also presents the possibility of more serious effects such as increased risk of heart attack and stroke, and tolerance or dependency issues. Surgical strategies tend to be reserved for more severe cases and are limited by the risks and complications typically associated with surgery including bleeding, bruising, scarring, and infection. A nonsurgical, minimally invasive, long-lasting approach to chronic pain management is desirable.

The Cryo-Touch III is a pain management device developed for a novel, minimally invasive procedure using focused cold therapy to target sensory nerve tissue and offer long-lasting pain relief through cryoanalgesia. The device operates on the well-established cryobiology principle that localized exposure to controlled moderately low temperature conditions can alter tissue function. The therapy treats nerves with low temperatures via a cold probe in the form of an assembly of small diameter needles, creating a highly localized treatment zone around the probe. This focused cold therapy creates a conduction block that prevents nerve signaling.

Though studies have proven efficacious in targeting motor nerves, the device's effect on sensory nerves has yet to have been investigated in the clinical setting. The goal of the study described herein is to evaluate the degree and duration of effect of the Cryo-Touch III in reducing chronic pain by targeting sensory nerves.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female, 18 years of age and older.
  • Participants must meet American College of Rheumatology (ACR) criteria for osteoarthritis of the knee (unilateral or bilateral). Clinical criteria includes knee pain and at least three of the following 6 criteria: 50 years of age or older, stiffness lasting less than 30 minutes, crepitus, bony tenderness, bony enlargement, and/or no warmth to the touch.
  • Any medications (prescription and/or over-the counter) must be maintained on a stable schedule for ≥ 2 weeks prior to treatment. No washout period is allowed.
  • An average Visual Analog Scale (VAS) for pain ≥ 4 over the last 30 days.
  • Subject is willing and able to give written informed consent.
  • Subject is willing and able to comply with study instructions and commit to all follow-up visits for the duration of the study.
  • Subject is in good general health and free of any systemic disease state or physical condition that might impair evaluation or which in the investigator's opinion, exposes the subject to an unacceptable risk by study participation.

Exclusion Criteria:

  • A partial or full knee replacement (in the treated knee).
  • Any use of systemic injections (in any area) within the last 6 months.
  • Current enrollment in an investigational drug or a device study that specifically targets pain treatment.
  • Any additional diagnosis that in the opinion of the investigator may directly contribute to knee pain.
  • Any concomitant inflammatory disease or other condition that affects the joints (e.g. rheumatoid arthritis, metabolic bones disease, gout, active infection, etc.).
  • Any clotting disorder and/or has used an anticoagulant (e.g., warfarin, clopidogrel, etc.) within seven (7) days prior to administration of the device.
  • Allergy or intolerance to lidocaine.
  • Any local skin condition at the treatment site that in the investigator's opinion would adversely affect treatment or outcomes.
  • Any chronic medical condition that in the investigator's opinion would prevent adequate participation.
  • Any chronic medication use (prescription, over-the-counter, etc.) that in the investigator's opinion would affect study participation or subject safety.
  • For any reason, in the opinion of the investigator, the subject may not be a suitable candidate for study participation (i.e., history of noncompliance, drug dependency, any related knee injury due to a worker's compensation claim, etc.).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01704157

Locations
United States, California
Neurovations
Napa, California, United States, 94557
United States, Idaho
Injury Care Medical Center
Boise, Idaho, United States, 83713
Sponsors and Collaborators
MyoScience, Inc
  More Information

No publications provided

Responsible Party: MyoScience, Inc
ClinicalTrials.gov Identifier: NCT01704157     History of Changes
Other Study ID Numbers: MYO-0601, Pain-OA
Study First Received: October 5, 2012
Last Updated: January 27, 2014
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by MyoScience, Inc:
Osteoarthritis
knee
chronic pain

Additional relevant MeSH terms:
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases

ClinicalTrials.gov processed this record on July 10, 2014